Figure 1.

INT131 improves insulin resistance similar to rosiglitazone in db/db mice. (A) Fasting blood glucose (FBG) was monitored in male db/db mice every 3 days after treatment with vehicle, 10 mg kg⁻¹ rosiglitazone (RSG), 10 mg kg⁻¹ INT131 (INT131 10), or 30 mg kg⁻¹INT131 (INT131 30). (B) The insulin tolerance test (ITT). Insulin (1 U kg⁻¹) was administered by i.p. injection to 6-h-fasted db/db mice after 12 days of treatment. (C) Area under the curve for the ITT curve. (D) Serum TG, (E) FFA, (F) Cholesterol, and (G) Adiponectin. (H–K) Body weight, WAT, BAT and liver index determined at the end of the experiment. MC, model control; n = 5–6 for each group. Multiple comparisons were performed with one-way ANOVA followed by Tukey's multiple comparison tests. Data are mean ± SE. ^*p < 0.05 compared with the MC.